Compare CINT & DNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CINT | DNA |
|---|---|---|
| Founded | 1995 | 2008 |
| Country | Brazil | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 566.6M | 607.1M |
| IPO Year | 2021 | N/A |
| Metric | CINT | DNA |
|---|---|---|
| Price | $5.00 | $6.72 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 5 | 2 |
| Target Price | $6.80 | ★ $10.50 |
| AVG Volume (30 Days) | 155.5K | ★ 978.5K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $13.00 | N/A |
| Revenue Next Year | $12.62 | $3.07 |
| P/E Ratio | $17.94 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.98 | $5.00 |
| 52 Week High | $7.28 | $17.58 |
| Indicator | CINT | DNA |
|---|---|---|
| Relative Strength Index (RSI) | 54.96 | 34.04 |
| Support Level | $4.93 | N/A |
| Resistance Level | $5.24 | $10.05 |
| Average True Range (ATR) | 0.19 | 0.71 |
| MACD | -0.01 | -0.14 |
| Stochastic Oscillator | 72.41 | 0.81 |
CI&T Inc is engaged in providing plans, design, and software engineering services to enable digital transformation for companies. The company mainly develops customizable software through the implementation of several software solutions, including Machine Learning, Artificial Intelligence (AI), Analytics, Cloud, and Mobility technologies. The majority of the revenue is generated from the North America and Europe, followed by Asia, Pacific and Japan.
Ginkgo Bioworks Holdings Inc is the platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. The Company reorganized its operations into two operating and reportable segments: Cell Engineering: where company provide biological R&D services for customers across a range of industries and Biosecurity: where it provide services to government and commercial customers to identify, monitor, prevent, mitigate, and ultimately protect humanity from biological threats. The maximum of revenue is from Cell Engineering Segment.